FDA Joins Forces With Customs Office To Beef Up Scrutiny of Drug Packages At Borders

The US FDA and the US customs office have agreed to team up and establish an expanded scientific presence at International Mail Facility locations deemed “high risk” ports of entry to deter illegal opioids and counterfeit drugs from entering US borders.

Gottlieb and Rep. Michael Burgess R-Texas, chairman of the House Energy and Commerce health subcommittee, as they toured the international mail facility at New York City’s JFK Airport on March 5.
A recent tour of an international mail facility by Rep. Michael Burgess, R-Texas, (left) and FDA Commissioner Scott Gottlieb (center)

The FDA and the US Customs and Border Protection (CBP) have agreed to join forces and "maximize inspection and detection capabilities" in deterring the illegal entry of unapproved fentanyl products, counterfeit prescriptions and over-the-counter drugs at the border.

As part of the agreement, signed on April 4, participants plan to establish an expanded scientific presence at International...

More from Manufacturing

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.

EUCOPE Wants Simpler Manufacturing Rules And Framework For Combined Trials Under EU Biotech Act

 

EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.

UK MHRA Helps Sponsors Prepare For ‘World’s First’ Decentralized Manufacturing Framework

 

The UK drug regulator, the MHRA, is set to launch its decentralized manufacturing framework in July, and has issued a series of guidance documents that it believes will help companies and also be of value to other countries that are considering how best to regulate the fledging sector.

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By 

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

More from Compliance

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

Novo, Lilly Ad Challenges Cause Discontinued Claims For Compounded GLP-1s

 
• By 

Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.

EU Emergency Response Authority Needs Bigger Budget To Address Health Threats, Says Industry

 

The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.